ClinicalTrials.gg
CompletedNCT01880736Updated Feb 10, 2017Results posted

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-02-10.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
23rd of 70
458 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
36th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 36th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current treatment with IGlar (insulin glargine) with or without OADs (oral antidiabetic drug). All antidiabetic treatments should have been on-going for at least 12 weeks prior to randomisation, and doses of OADs should have been stable in this period of time. - Please note that a maximum of 3 OADs are allowed during this trial: metformin, sulphonylurea (SU)/glinides, dipeptidyl peptidase 4 (DPP-IV) inhibitors, alfa-glucosidaseinhibitors or pioglitazone.
  • Diagnosis of T2DM (type 2 diabetes mellitus) at the discretion of the investigator for at least 26 weeks prior to visit 1 (Screening visit)
  • 7.0-9.5% (both inclusive) by central laboratory analysis
  • (BMI) equal to or below 35 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Any chronic disorder or severe disease which, in the opinion of the Investigator might jeopardise subject's safety or compliance with the protocol
  • Stroke; decompensated heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 26 weeks prior to Visit 1 (Screening visit)
  • Impaired renal function, defined as serum-creatinine higher than or equal to 1.4 mg/dL for males and higher than or equal to 1.3 mg/dL for females
  • Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)
  • Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 12 weeks prior to randomisation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    IDeg OD Flexible Dose

    Drug: insulin degludec

  • Experimental
    IDeg OD Fixed Dose

    Drug: insulin degludec

  • Experimental
    IDeg OD Simple

    Drug: insulin degludec

  • Experimental
    IDeg OD Stepwise

    Drug: insulin degludec

Interventions

  • Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

  • Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.

  • Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)

    Changes from baseline in HbA1c values over time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise)

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Changes from baseline in FPG values over the time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

    Time frame: Week 0, week 26

  2. Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial

    The number of subjects who achieved the pre-defined HbA1c target (\<7.0%) after 26 weeks of treatment was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

    Time frame: After 26 weeks of treatment

  3. Incidence of Treatment Emergent Adverse Events (TEAEs)

    The incidences of treatment emergent adverse events (TEAEs) over the time period of Week 0-26 were recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).

    Time frame: Weeks 0-26

  4. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))

    The confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L \[less than 56 mg/dL\]) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).

    Time frame: Weeks 0-26

  5. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) Definition

    Number of treatment emergent hypoglycaemic episodes according to the ADA definition (classified as severe hypoglycaemia, documented hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia, relative hypoglycaemia) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

    Time frame: Weeks 0-26

  6. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period

    The number of treatment mergent confirmed hypoglycaemic episodes in the maintenance period from Week 16 to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs. stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.

    Time frame: From Week 16 to end of trial (week 27)

  7. Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes

    The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Weeks 0-26

  8. Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period

    The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period from 16 weeks to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: From week 16 to end of trial (week 27)

08

Results

Posted Mar 17, 2016

Participant flow

The trial was conducted at 39 sites in Japan.

Participant flow — Overall Study
MilestoneIDeg OD Fixed Dosing and Simple Titration (Arm A)IDeg OD Fixed Dosing and Stepwise Titration (Arm B)IDeg OD Flexible Dosing and Simple Titration (Arm C)IDeg OD Flexible Dosing and Stepwise Titration (Arm D)
Started114115115114
Completed113113114108
Not completed1216
Withdrew: Adverse event0001
Withdrew: Withdrawal criteria1215

Outcome measures

PrimaryChange From Baseline in HbA1c (%) Glycosylated Haemoglobin)

Changes from baseline in HbA1c values over time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise)

Time frame:
Week 0, week 26
Reported as:
Mean · Percent (%) glycosylated haemoglobin
Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)
Percent (%) glycosylated haemoglobinIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)-0.54 ± 0.76-0.62 ± 0.75-0.57 ± 0.72-0.59 ± 0.80
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Changes from baseline in FPG values over the time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

Time frame:
Week 0, week 26
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG)
mg/dLIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Change From Baseline in Fasting Plasma Glucose (FPG)-28.8 ± 39.0-25.4 ± 40.2-27.0 ± 35.3-27.2 ± 43.6
SecondaryResponder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial

The number of subjects who achieved the pre-defined HbA1c target (\<7.0%) after 26 weeks of treatment was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

Time frame:
After 26 weeks of treatment
Reported as:
Number · Subjects
Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial
SubjectsIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial90959194
SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs)

The incidences of treatment emergent adverse events (TEAEs) over the time period of Week 0-26 were recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).

Time frame:
Weeks 0-26
Reported as:
Number · events
Incidence of Treatment Emergent Adverse Events (TEAEs)
eventsIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Incidence of Treatment Emergent Adverse Events (TEAEs)150154138166
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))

The confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L \[less than 56 mg/dL\]) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))
episodesIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))476371469378
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) Definition

Number of treatment emergent hypoglycaemic episodes according to the ADA definition (classified as severe hypoglycaemia, documented hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia, relative hypoglycaemia) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) Definition
episodesIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
ADA Events Overall3053273630892700
Severe0110
Documented symptomatic1262114112931110
Asymptomatic1523128315051301
Probable symptomatic87131103115
Relative181180187174
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period

The number of treatment mergent confirmed hypoglycaemic episodes in the maintenance period from Week 16 to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs. stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.

Time frame:
From Week 16 to end of trial (week 27)
Reported as:
Number · episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period
episodesIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period227192241178
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes

The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes
episodesIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes77588055
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period

The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period from 16 weeks to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
From week 16 to end of trial (week 27)
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period
episodesIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period34234017

Adverse events

Collected over This included events from the first trial related activity after the subject had signed the informed consent and until the end of the follow-up period (Week 27).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg OD Flexible (Arm C+Arm D)—8/229 (3.5%)79/229 (34.5%)
IDeg OD Fixed (Arm A+Arm B)—6/229 (2.6%)82/229 (35.8%)
IDeg OD Simple (Arm A+Arm C)—7/229 (3.1%)78/229 (34.1%)
IDeg OD Stepwise (Arm B+Arm D)—7/229 (3.1%)83/229 (36.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
HypoglycaemiaMetabolism and nutrition disorders0/2292/2291/2291/229
Acute myocardial infarctionCardiac disorders0/2291/2290/2291/229
Arteriosclerosis coronary arteryCardiac disorders1/2290/2290/2291/229
Left ventricular hypertrophyCardiac disorders1/2290/2290/2291/229
EnterocolitisGastrointestinal disorders1/2290/2291/2290/229
Non-cardiac chest painGeneral disorders0/2291/2291/2290/229
CellulitisInfections and infestations1/2290/2291/2290/229
PneumoniaInfections and infestations0/2291/2291/2290/229
Joint dislocationInjury, poisoning and procedural complications1/2290/2291/2290/229
Upper limb fractureInjury, poisoning and procedural complications0/2291/2291/2290/229
Most frequent other events
Most frequent other events
EventIDeg OD Flexible (Arm C+Arm D)IDeg OD Fixed (Arm A+Arm B)IDeg OD Simple (Arm A+Arm C)IDeg OD Stepwise (Arm B+Arm D)
NasopharyngitisInfections and infestations67/22969/22968/22968/229
Diabetic retinopathyEye disorders24/22920/22918/22926/229

Baseline characteristics

The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".

Age, Continuous
Age, Continuous(years)IDeg OD Fixed Dosing and Simple Titration (Arm A)IDeg OD Fixed Dosing and Stepwise Titration (Arm B)IDeg OD Flexible Dosing and Simple Titration (Arm C)IDeg OD Flexible Dosing and Stepwise Titration (Arm D)Total
Mean60.4 ± 10.660.7 ± 10.560.0 ± 10.860.2 ± 10.860.3 ± 10.7
Gender
Gender(Participants)IDeg OD Fixed Dosing and Simple Titration (Arm A)IDeg OD Fixed Dosing and Stepwise Titration (Arm B)IDeg OD Flexible Dosing and Simple Titration (Arm C)IDeg OD Flexible Dosing and Stepwise Titration (Arm D)Total
Female41415034166
Male73746580292
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDeg OD Fixed Dosing and Simple Titration (Arm A)IDeg OD Fixed Dosing and Stepwise Titration (Arm B)IDeg OD Flexible Dosing and Simple Titration (Arm C)IDeg OD Flexible Dosing and Stepwise Titration (Arm D)Total
Mean7.8 ± 0.67.8 ± 0.67.8 ± 0.57.8 ± 0.67.8 ± 0.6
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)IDeg OD Fixed Dosing and Simple Titration (Arm A)IDeg OD Fixed Dosing and Stepwise Titration (Arm B)IDeg OD Flexible Dosing and Simple Titration (Arm C)IDeg OD Flexible Dosing and Stepwise Titration (Arm D)Total
Mean129.8 ± 30.0136.0 ± 38.1131.8 ± 33.5134.5 ± 39.6133.0 ± 35.5
09

Study locations

40 sites
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0002, Japan
  • Novo Nordisk Investigational Site
    Chuo-ku, Tokyo, 103 0027, Japan
  • Novo Nordisk Investigational Site
    Fukui-shi, Fukui, 918-8503, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 812 0025, Japan
  • Novo Nordisk Investigational Site
    Gifu-shi, Gifu, 501-1194, Japan
  • Novo Nordisk Investigational Site
    Izumisano-shi, 598 0048, Japan
  • Novo Nordisk Investigational Site
    Kagoshima-shi, Kagoshima, 890-8520, Japan
  • Novo Nordisk Investigational Site
    Kamakura-shi, 247 0056, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582 0005, Japan
  • Novo Nordisk Investigational Site
    Katsushika-ku, Tokyo, 125 0054, Japan
  • Novo Nordisk Investigational Site
    Kawasaki-shi, Kanagawa, 216-8511, Japan
  • Novo Nordisk Investigational Site
    Kitakyushu-shi, Fukuoka, 800 0252, Japan
  • Novo Nordisk Investigational Site
    Kitakyushu-shi, Fukuoka, 807-8555, Japan
  • Novo Nordisk Investigational Site
    Kitakyusyu-shi, Fukuoka, 800-0222, Japan
  • Novo Nordisk Investigational Site
    Koriyama-shi, Fukushima, 963 8851, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi,Kumamoto, 862 0976, Japan
  • Novo Nordisk Investigational Site
    Mito-shi, Ibaraki, 310-0845, Japan
  • Novo Nordisk Investigational Site
    Miyazaki-shi, 880 0034, Japan
  • Novo Nordisk Investigational Site
    Naka-shi, Ibaraki, 311 0113, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 951-8520, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, Hyogo, 663-8501, Japan
  • Novo Nordisk Investigational Site
    Oita-shi, 870 0039, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831 0016, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 532 0003, Japan
  • Novo Nordisk Investigational Site
    Oyama-shi, Tochigi, 323 0022, Japan
  • Novo Nordisk Investigational Site
    Sakaide-shi, Kagawa, 762-0031, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060 0062, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 060-0001, Japan
  • Novo Nordisk Investigational Site
    Sapporo-shi, Hokkaido, 062 0007, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, 980 0021, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329 0433, Japan
  • Novo Nordisk Investigational Site
    Suita-shi, Osaka, 565-0853, Japan
  • Novo Nordisk Investigational Site
    Takatsuki-shi, Osaka, 569 1096, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0028, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 113-8655, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 123-0845, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 143-8541, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 144-0051, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 162-8655, Japan
  • Novo Nordisk Investigational Site
    Yokkaichi-shi, Mie, 510-0829, Japan
10

References and documents

Publications

  • Kadowaki T, Jinnouchi H, Kaku K, Herslov ML, Hyllested-Winge J, Nakamura S. Insulin degludec in a simple or stepwise titration algorithm in a Japanese population of patients with type 2 diabetes: a randomized, 26-week, treat-to-target trial. Diabetol Int. 2016 Sep 2;8(1):87-94. doi: 10.1007/s13340-016-0284-9. eCollection 2017 Mar. PubMed 30603311 ↗
  • Kadowaki T, Jinnouchi H, Kaku K, Herslov ML, Hyllested-Winge J, Nakamura S. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. J Diabetes Investig. 2016 Sep;7(5):711-7. doi: 10.1111/jdi.12502. Epub 2016 Apr 1. PubMed 27182031 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2013
First posted
Jun 19, 2013
Start
Jun 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Mar 17, 2016
Last update
Feb 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01880736
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 19, 2013
Start date
Jun 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Mar 17, 2016
Last update
Feb 10, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion